Center for Drug Evaluation and Research Prescription Drug Labeling Improvement and Enhancement Initiative; Request for Comments and Information

This Notice document was issued by the Food and Drug Administration (FDA)

For related information, Open Docket Folder


DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 201, 314, and 601
[Docket No. FDA-2013-N-0059]

Center for Drug Evaluation and Research; Prescription Drug Labeling Improvement and Enhancement Initiative; Request for Comments and Information

Agency

Food and Drug Administration, HHS.

Action

Notification of an initiative; request for comments and information.

Summary

The Food and Drug Administration (FDA) is announcing the establishment of a docket to receive comments on the proposed implementation of FDA's Prescription Drug Labeling Improvement and Enhancement Initiative and on a proposed pilot project relating to the voluntary conversion of labeling to the “Physician Labeling Rule (PLR)” format described in the 2006 FDA final rule, “Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products.” The purpose of the initiative and the pilot project is to enhance the safe and effective use of prescription drugs by facilitating optimal communication through labeling. FDA is seeking public comment on this initiative, and the pilot project, particularly from stakeholders who develop and use prescription drug labeling. Comments received from stakeholders will assist the Agency in identifying and addressing feasibility and implementation issues associated with this initiative.

Dates

Submit either electronic or written comments by March 8, 2013.

Addresses

Submit electronic comments to . Submit written comments to the Division of Dockets Management (HFA-301), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Identify comments with the docket number found in brackets in the heading of this document.

For Further Information Contact

Connie Wisner, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6360, Silver Spring, MD 20993-0002, 301-796-8509, FAX: 301-847-3529, email: .

Supplementary Information

I. Background

Prescription drug labeling, commonly called the package insert or prescribing information, is a compilation of information approved by FDA about the safe and effective use of the product, based on FDA's thorough analysis of the new drug application (NDA) or biologics license application (BLA) submitted by the applicant. Its primary purpose is to provide health care practitioners with the essential information needed to facilitate prescribing decisions, thereby enhancing the safe and effective use of prescription drug products and reducing the likelihood of medication errors.

FDA implemented standardized prescription drug labeling in 1979 (44 FR 37434, June 26, 1979). However, over the ensuing 25 years, labeling became increasingly lengthy and complex, which affected its usefulness to healthcare professionals. To address this issue, FDA evaluated the usefulness of prescription drug labeling among healthcare professionals to determine whether and how its content and format could be improved and completed a rulemaking focused on enhanced prescription drug labeling.

In 2006, FDA published the final rule, “Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products,” which revised the content and format requirements for labeling to make it easier to access, read, and use (71 FR 3922, January 24, 2006). The rule is commonly referred to as the “Physician Labeling Rule” (PLR or final rule) because it addresses prescription drug labeling that is used by prescribers, including physicians and other healthcare practitioners. (1)

The final rule applies to products for which an NDA, BLA, or efficacy supplement (ES) was approved between June 30, 2001, and June 30, 2006, and to NDAs, BLAs, and ESs submitted after June 30, 2006. The rule established a staggered implementation schedule, under which cohorts of drugs, from newest to oldest would be converted to the new labeling format over time. (2) The staged implementation for PLR conversion expires on June 30, 2013. (3) Older drugs approved before June 30, 2001, are not subject to the mandatory PLR conversion requirement, but FDA strongly encourages all applicants to voluntarily convert the labeling of their drug products to the PLR format, regardless of the date of approval.

As of November 2012, approximately 15 percent of all prescription drugs and biological products have labeling in the PLR format. (4) If no further action is taken, the only additional drug products with labeling in the PLR format will be new NDAs, BLAs, and ES, which are required to be submitted in PLR format, and labeling for drug products for which the NDA or BLA holder voluntarily converts to PLR format.

Generic drugs approved under an abbreviated new drug application (ANDA) are not required to convert their labeling to PLR format unless the reference-listed drug (RLD) approved in an NDA has converted to PLR format. Recent data show that only 10 percent of generic drug labeling has been converted to the PLR format. (5) Since nearly 80 percent of prescriptions today are filled with generic drugs, (6) FDA believes that it is in the best interest of the public health to facilitate conversion of generic drug labeling to the PLR format so the labeling is equally useful to prescribers as the labeling for more recently approved drug products.

Additional FDA outreach corroborates the usefulness of drug labeling in PLR format. On April 20, 2012, the Brookings Institute Engelberg Center for Health Care Reform, in cooperation with FDA, held an expert meeting  (7) to obtain feedback from healthcare practitioners on the utility of the prescription drug labeling as a communication tool and to discuss strategies for making it more accessible. In general, meeting participants were very supportive of the PLR format and in agreement that it improves accessibility and use in electronic systems. Moreover, stakeholders, particularly physicians and pharmacists, requested that all labeling be available in PLR format, including labeling for generic drugs and older drug products outside the current PLR implementation schedule.

All holders of marketing applications for drugs and biological products have an ongoing obligation to ensure their labeling is accurate and up-to-date. For example, when new information comes to light that causes information in labeling to become inaccurate, the application holder must take steps to change the content of its labeling, in accordance with 21 CFR 314.70, 314.97, and 601.12. The PLR format represents a more useful and modern approach for communicating accurate and up-to-date information on the safe and effective use of drugs and makes prescription information more accessible for use with electronic prescribing tools and other electronic information resources. For these reasons, FDA is proposing to implement the Prescription Drug Labeling Improvement and Enhancement Initiative to ensure that the safe and effective use of prescription drugs is communicated optimally through labeling.

II. Prescription Drug Labeling Improvement and Enhancement Initiative

The focus of the initiative is to increase the number of drugs with labeling that complies with the PLR content and format requirements (§§ 201.56(d) and 201.57) for drugs approved before June 30, 2001, and for generic drugs. The initiative is anticipated to take place over several years. FDA intends to request that applicants with NDAs, BLAs, or ESs approved before June 30, 2001, and generic drugs for which the NDA for the RLD has been withdrawn (for reasons other than safety or effectiveness) voluntarily convert their labeling to PLR format and submit it to FDA for approval. (8) FDA intends to identify and prioritize certain drugs and drug classes based on public health impact (e.g., most prescribed, higher risk).

As part of the initiative, FDA is considering, through the use of a Government contractor, providing PLR conversion resources and services, including preparation of draft PLR labeling for applicants who request FDA's assistance to convert labeling to PLR format. For draft labeling converted to PLR format by a Government contractor, FDA would review the draft labeling prepared by the contractor and then send the applicant the proposed draft PLR format labeling. The applicant would then submit a labeling supplement to FDA with its proposed PLR format labeling (which may include proposed revisions to the draft PLR labeling). It should be emphasized that the application holder always bears responsibility for the content of its product labeling, and FDA's provision of contract resources is intended to facilitate conversion to the PLR format.

This initiative differs from the original PLR implementation plan in the final rule in that the Agency is not proposing rulemaking at this time. Rather, FDA would like to explore a voluntary approach to PLR conversions with NDA and BLA holders for drugs approved before June 30, 2001, and ANDA holders for drugs for which the NDA for the RLD has been withdrawn. In light of the public health benefit realized by labeling in PLR format, and previous interest by many ANDA holders in converting labeling for their drug products to PLR format, FDA anticipates that application holders will be interested in participating in this voluntary approach to enhance communication of information about the drug's safe and effective use through product labeling.

To determine the best approach to accomplish the objectives of this initiative, FDA is considering performing a pilot project to identify best practices and to standardize the approach for voluntary PLR format conversions. FDA is seeking interested applicants with NDAs, BLAs, or ESs approved before June 30, 2001, and generic drugs for which the NDA for the RLD has been withdrawn to voluntarily participate in this pilot project.

III. Establishment of a Docket and Request for Comments and Information

FDA is soliciting public comments on the Prescription Drug Improvement and Enhancement Initiative. FDA is specifically seeking feedback on the following:

1. What specific feasibility issues or other factors should FDA consider in its proposed pilot project and implementation of the Prescription Drug Labeling Improvement and Enhancement Initiative?

2. What factors should FDA consider in identifying and prioritizing drugs and/or drug classes for voluntary PLR conversions?

3. What approaches would application holders find helpful in facilitating voluntary PLR conversions for the specified drugs or drug classes? For example, please comment on the following approaches for communicating with applicants:

  • Inquiry letter that identifies a drug proposed for PLR format conversion and requests information from the application holder regarding its preferred approach for possible PLR conversion (i.e., application holder or Government contractor)?
  • Supplement request letter with draft labeling that has been converted to the PLR format attached?

4. For generic drugs for which the NDA for the RLD has been withdrawn, what procedures should FDA use to harmonize feedback from multiple ANDA holders on proposed draft labeling in the PLR format?

5. Would your company be interested in participating in the pilot project and the broader Prescription Drug Improvement and Enhancement Initiative? Why or why not?

Suggestions, recommendations, or comments should describe relevant considerations that may impact the feasibility or implementation of the initiative or the impact the initiative may have on prescription drug labeling issues. We also encourage commenters to include recommendations on how such prescription drug labeling issues could be addressed.

FDA will consider all suggestions, recommendations, and comments; however, the Agency will not respond directly to the person or organization making the suggestion, recommendation, or comment.

IV. Comments

Interested persons may submit either electronic comments information regarding this document to or written comments to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments or information. Identify comments or information with the docket number found in brackets in the heading of this document. Received comments or information may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at .

Dated: January 31, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-02528 Filed 2-5-13; 8:45 am]
BILLING CODE 4160-01-P

Footnotes

(1)  In this Federal Register document, the term “PLR format” refers to labeling that meets the content and format requirements at §§ 201.56(d) and 201.57 (21 CFR 201.56(d) and 201.57). The term “old format” refers to labeling that meets the requirements at § 201.56(e) and 21 CFR 201.80.

(2)  See § 201.56(c). The Agency adopted this approach because research conducted during the final rule's development indicated that this was the “most reasonable approach to maximizing the public health benefit and best utilizing available resources.” See 71 FR 3922 at 3962, January 24, 2006.

(3)  The last cohort of drugs approved from June 30, 2001, to June 29, 2002, must submit PLR conversion supplements to FDA by June 30, 2013.

(4)  Data obtained from .

(5)  Ibid.

(6)  See .

(7)  For more information on the Expert Meeting, see . (FDA has verified the Web site address, but FDA is not responsible for any subsequent changes to the Web site after this document publishes in the Federal Register.)

(8)  See §§ 314.150(a) and (b). An NDA holder that has discontinued marketing a drug product, but has not requested withdrawal of the NDA, must still comply with applicable statutory and regulatory requirements. Such requirements include, for example, submission of an annual report (including a brief summary of significant new information from the previous year that might affect the safety, effectiveness, or labeling of the drug product, and a description of actions the applicant has taken or intends to take as a result of this new information) and, if appropriate, proposed revisions to product labeling.

 
 
Comment Period Closed
Mar 8 2013, at 11:59 PM ET
ID: FDA-2013-N-0059-0001
View original printed format:
PDF

Document Information

Date Posted: Feb 6, 2013
Federal Register Number: 2013-02528
Show More Details  

Comments

15
Comments Received*
See attached file(s)
See attached file(s)
See attached file(s)

Docket Information

This document is contained in
Related Dockets:
None
Related RINs: None
Related Documents:
None
Related Comments:

* This count refers to the total comment/submissions received on this document, as of 11:59 PM yesterday. Note: Agencies review all submissions, however some agencies may choose to redact, or withhold, certain submissions (or portions thereof) such as those containing private or proprietary information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. This can result in discrepancies between this count and those displayed when conducting searches on the Public Submission document type. For specific information about an agency’s public submission policy, refer to its website or the Federal Register document.

Document text and images courtesy of the
Federal Register